CLDN1, INHBA, and CXCL12 may serve as clinically relevant biomarkers in CRC, particularly as prognostic indicators linked to tumor progression, immune modulation, and metastatic potential. This evidence concerns the gene CLDN1 and colorectal carcinoma.